Cryoport, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam Sells 1,895 Shares

Cryoport, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 1,895 shares of the firm’s stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $7.01, for a total value of $13,283.95. Following the completion of the sale, the director now directly owns 67,001 shares in the company, valued at approximately $469,677.01. This represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ramkumar Mandalam also recently made the following trade(s):

• On Friday, June 13th, Ramkumar Mandalam sold 624 shares of Cryoport stock. The stock was sold at an average price of $6.80, for a total value of $4,243.20.
• On Wednesday, June 11th, Ramkumar Mandalam sold 8,193 shares of Cryoport stock. The shares were sold at an average price of $7.06, for a total transaction of $57,842.58.
• On Monday, June 9th, Ramkumar Mandalam sold 5,622 shares of Cryoport stock. The stock was sold at an average price of $7.06, for a total transaction of $39,691.32.

Cryoport Stock Down 3.3%

Shares of NASDAQ CYRX opened at $6.67 on Friday. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $10.37. The firm’s 50-day simple moving average is $6.07 and its 200 day simple moving average is $6.73. The company has a market cap of $334.41 million, a price-to-earnings ratio of -1.97 and a beta of 1.85. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. On average, research analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Cryoport

A number of institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Cryoport during the fourth quarter worth $51,000. Quarry LP bought a new stake in Cryoport in the fourth quarter valued at about $69,000. SBI Securities Co. Ltd. lifted its stake in Cryoport by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company’s stock valued at $67,000 after buying an additional 10,975 shares during the period. Finally, CWM LLC lifted its stake in Cryoport by 1,437.0% in the first quarter. CWM LLC now owns 11,328 shares of the company’s stock valued at $69,000 after buying an additional 10,591 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analyst Ratings Changes

CYRX has been the subject of several recent research reports. UBS Group increased their price target on shares of Cryoport from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st. Morgan Stanley dropped their target price on Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Monday, May 5th. Roth Mkm restated a “buy” rating and set a $15.00 target price on shares of Cryoport in a research report on Tuesday, April 1st. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.00.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.